INTRODUCTION: Primary sclerosing cholangitits (PSC) is a progressive fibrosing cholangiopathy eventually leading to end-stage liver disease (ESLD). While literature for deceased donor liver transplantation (DDLT) for PSC abounds, only a few reports describe live donor liver transplant (LDLT) in the setting of PSC. We present a single-center experience on survival outcomes and disease recurrence for LDLT and DDLT for ESLD secondary to PSC. AIM: The aim of this study was to analyze survival outcomes and disease recurrence for LDLT and DDLT for ESLD secondary to PSC. PATIENTS AND METHODS: A retrospective review of 58 primary liver transplants for PSC-associated ESLD, performed between May 1995 and January 2007, was done. Patients were divided into two groups based on donor status. Group 1 (n = 14) patients received grafts from living donors, while group 2 (n = 44) patients received grafts from deceased donors. An analysis of survival outcomes and disease recurrence was performed. Recurrence was confirmed based on radiological and histological criteria. RESULTS: Recurrence of PSC was observed in four patients in LDLT group and seven in DDLT group. Retransplantation was required in one patient in LDLT group and nine patients in DDLT group. One patient (7%) among LDLT and six patients (14%) among DDLT died. The difference in patient and graft survival was not statistically significant between the two groups (patient survival, p = 0.60; graft survival, p = 0.24). CONCLUSION: This study demonstrates equivalent survival outcomes between LDLT and DDLT for PSC; however, the rate of recurrence may be higher in patients undergoing LDLT.
INTRODUCTION:Primary sclerosing cholangitits (PSC) is a progressive fibrosing cholangiopathy eventually leading to end-stage liver disease (ESLD). While literature for deceased donor liver transplantation (DDLT) for PSC abounds, only a few reports describe live donor liver transplant (LDLT) in the setting of PSC. We present a single-center experience on survival outcomes and disease recurrence for LDLT and DDLT for ESLD secondary to PSC. AIM: The aim of this study was to analyze survival outcomes and disease recurrence for LDLT and DDLT for ESLD secondary to PSC. PATIENTS AND METHODS: A retrospective review of 58 primary liver transplants for PSC-associated ESLD, performed between May 1995 and January 2007, was done. Patients were divided into two groups based on donor status. Group 1 (n = 14) patients received grafts from living donors, while group 2 (n = 44) patients received grafts from deceased donors. An analysis of survival outcomes and disease recurrence was performed. Recurrence was confirmed based on radiological and histological criteria. RESULTS: Recurrence of PSC was observed in four patients in LDLT group and seven in DDLT group. Retransplantation was required in one patient in LDLT group and nine patients in DDLT group. One patient (7%) among LDLT and six patients (14%) among DDLT died. The difference in patient and graft survival was not statistically significant between the two groups (patient survival, p = 0.60; graft survival, p = 0.24). CONCLUSION: This study demonstrates equivalent survival outcomes between LDLT and DDLT for PSC; however, the rate of recurrence may be higher in patients undergoing LDLT.
Authors: M Kaibori; S Uemoto; S Fujita; Y Inomata; H Egawa; K Asonuma; T Kiuchi; M Hayashi; M Nakamura; K Tanaka Journal: Transpl Int Date: 1999 Impact factor: 3.782
Authors: D R Jeyarajah; G J Netto; S P Lee; G Testa; O Abbasoglu; B S Husberg; M F Levy; R M Goldstein; T A Gonwa; G W Tillery; J S Crippin; G B Klintmalm Journal: Transplantation Date: 1998-11-27 Impact factor: 4.939
Authors: Giovanni Varotti; Gabriel E Gondolesi; Sasan Roayaie; Arief Suriawinata; Kyle Soltys; Thomas M Fishbein; Myron E Schwartz; Charles Miller Journal: J Am Coll Surg Date: 2003-11 Impact factor: 6.113
Authors: Matthew A Morgan; Rachita Khot; Karthik M Sundaram; Daniel R Ludwig; Rashmi T Nair; Pardeep K Mittal; Dhakshina M Ganeshan; Sudhakar K Venkatesh Journal: Abdom Radiol (NY) Date: 2022-09-05
Authors: Fredric D Gordon; David S Goldberg; Nathan P Goodrich; Anna S F Lok; Elizabeth C Verna; Nazia Selzner; R Todd Stravitz; Robert M Merion Journal: Liver Transpl Date: 2016-08-02 Impact factor: 5.799
Authors: Chuan Li; Kai Mi; Tian fu Wen; Lu nan Yan; Bo Li; Jia ying Yang; Ming qing Xu; Wen tao Wang; Yong gang Wei Journal: PLoS One Date: 2011-11-07 Impact factor: 3.240
Authors: Iris C Steenstraten; Kerem Sebib Korkmaz; Palak J Trivedi; Akin Inderson; Bart van Hoek; Mar D M Rodriguez Girondo; P W Jeroen Maljaars Journal: Aliment Pharmacol Ther Date: 2019-02-10 Impact factor: 8.171